4D Pharma

47 articles with 4D Pharma

• 4D pharma Announces Two Presentations at European Society for Medical Oncology (ESMO) Congress 2021

  8/2/2021

  4D pharma plc, a pharmaceutical company leading the development of Live Biotherapeutic products, a novel class of drug derived from the microbiome, announces two poster presentations at the European Society for Medical Oncology Congress, held from September 16-21, 2021.

• 4D pharma Announces Passing of Chief Financial Officer John Beck

  7/26/2021

  4D pharma plc announces with great sadness that John Beck, Chief Financial Officer of 4D pharma, has passed away.

• 4D pharma Announces Publication of Preclinical Research Showing Single Strain Megasphaera massiliensis improves activity of CAR-T

  7/6/2021

  4D pharma plc today announces the publication of pre-clinical research relating to its second-generation immuno-oncology LBP MRx1299 improving the activity of CAR-T.

• 4D pharma to Participate in Ladenburg Thalmann Healthcare Conference

  6/29/2021

  4D pharma plc, a pharmaceutical company leading the development of Live Biotherapeutic products, a novel class of drug derived from the microbiome, announces that Duncan Peyton, Chief Executive Officer, and Alex Stevenson, Chief Scientific Officer, will present a corporate overview followed by a fireside chat at the virtual Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021, at 2:30pm ET.

• 4D pharma to Present at the Microbiome Movement Drug Development Summit

  6/22/2021

  4D pharma plc announces Christophe Carite, Development Director, will deliver a presentation on 4D pharma’s strategy and capabilities for the manufacturing of its Live Biotherapeutic drug candidates at the upcoming virtual Microbiome Movement Drug Development Summit, on Thursday, July 1 at 2.15pm EDT.

• 4D pharma Completes Enrollment of Part A of the Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma and Provides Program Update

  6/4/2021

  - Topline data from Part A of asthma study expected in 2H 2021 - Discontinuation of enrollment in Phase II study of MRx-4DP0004 for the treatment of hospitalized patient with COVID-19

• 4D pharma Presents Additional Positive Results of Phase II Study of Blautix® for the Treatment of Irritable Bowel Syndrome

  5/24/2021

  4D pharma plc, a pharmaceutical company leading the development of Live Biotherapeutic products - a novel class of drug derived from the microbiome, announces additional positive data from its completed Phase II trial of LBP Blautix® in subjects with irritable bowel syndrome with constipation or with diarrhea.

• 4D pharma to Present Additional Data from Phase II Study of Blautix for the Treatment of Irritable Bowel Syndrome at Digestive Disease Week (DDW) 2021

  5/17/2021

  4D pharma plc, a pharmaceutical company leading the development of Live Biotherapeutic products - a novel class of drug derived from the microbiome, announced that it will present data from its Phase II study of single strain LBP Blautix® in patients with irritable bowel syndrome subtypes IBS-C and IBS-D in a poster session at Digestive Disease Week 2021, taking place virtually May 21-23, 2021.

• 4D pharma Collaborates With Parkinson’s UK to Establish Patient Advisory Board

  4/19/2021

  4D pharma plc (AIM: DDDD; NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces a collaboration with Parkinson’s UK, a non-profit organization focused on advancing the understanding of Parkinson’s disease and improving treatments, to establish a Patient Advisory Board.

• Final Results for the year ended 31 December 2020

  4/1/2021

  4D pharma plc (AIM: DDDD, NASDAQ: LBPS) (“4D”, the “Company” or, together with its subsidiaries, the “Group”), a pharmaceutical company leading the development of Live Biotherapeutics, is pleased to announce the final results for the Group for the year ended 31 December 2020.

• Completion of Merger With Longevity Acquisition Corporation and Admission of American Depositary Shares to Trading on NASDAQ

  3/22/2021

  4D pharma plc, a pharmaceutical company leading the development of Live Biotherapeutic products, a novel class of drug derived from the microbiome, is pleased to announce that its business combination with Longevity Acquisition Corporation, details of which were announced on 22 October 2020, has now become effective.

• 4D pharma Announces Completion of Merger With Longevity Acquisition Corporation

  3/22/2021

  4D pharma plc, a pharmaceutical company leading the development of Live Biotherapeutic products - a novel class of drug derived from the microbiome - announced completion of its merger with Longevity Acquisition Corporation.

• 4D Pharma Announces Private Placement

  3/17/2021

  Company expects to complete merger with Longevity Acquisition Corporation and its American Depositary Shares to be admitted to trading on NASDAQ on 22 March 2021

• 4D Pharma to Present at Upcoming Investor Conferences in March

  3/3/2021

  4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announced that 4D management will present at three upcoming investor conferences:

•  4D Pharma Appointments Paul Maier to the Board as Non-Executive Director

  3/1/2021

  4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the appointment of Paul Maier as Non-Executive Director of the Board. Mr Maier will also be a member of 4D's Audit and Risk Committee and will serve as the Company’s “audit committee financial expert"

• 4D Pharma Appoints John Beck as Chief Financial Officer and Member of the Management Team

  3/1/2021

  4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the appointment of John Beck as Chief Financial Officer (CFO) and member of the Company’s management team

• 4D Pharma Announces U.S. SEC Declares Registration Statement Effective with Respect to the Issuance of 4D Pharma American Depositary Shares on NASDAQ

  2/26/2021

  4D pharma to list ADSs on NASDAQ in conjunction with the merger agreement between 4D pharma and Longevity Acquisition Corp., a SPAC

• 4D Pharma to Participate in Upcoming Cantor Fitzgerald Microbiome Leaders Panel

  2/16/2021

  4D pharma plc, a pharmaceutical company leading the development of Live Biotherapeutic products - a novel class of drug derived from the microbiome, announces Duncan Peyton, Chief Executive Officer of 4D pharma, will participate in Cantor Fitzgerald’s virtual panel, titled “Microbiome Players with Guided Readouts in 2021,” on Thursday, February 18, 2021 at 15:00 GMT.

• 4D pharma Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate MRx0518 in Combination with BAVENCIO® for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

  2/8/2021

  4D pharma Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate MRx0518 in Combination with BAVENCIO ® for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

• Longevity Acquisition Corporation Announces 4D pharma Update on Oncology Program

  2/3/2021

  Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that on February 3, 2021 , 4D pharma plc (AIM: DDDD) ("4D pharma"), a pharmaceutical company leading the development of Live Biotherapeutic products ("LBPs") has announced progress on activities in its development program